Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) PT at $54.64

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have earned a consensus rating of “Moderate Buy” from the twelve brokerages that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $54.64.

ANAB has been the topic of several analyst reports. JPMorgan Chase & Co. raised their target price on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Guggenheim raised their price objective on shares of AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a report on Monday, October 21st. Truist Financial boosted their target price on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. HC Wainwright restated a “buy” rating and issued a $55.00 price target on shares of AnaptysBio in a research note on Wednesday, August 14th. Finally, Wedbush reaffirmed an “outperform” rating and set a $42.00 price target on shares of AnaptysBio in a report on Thursday, September 26th.

AnaptysBio Trading Down 0.6 %

Shares of NASDAQ ANAB opened at $32.03 on Wednesday. The stock has a market cap of $875.03 million, a P/E ratio of -5.22 and a beta of -0.29. The business’s fifty day simple moving average is $35.45 and its 200-day simple moving average is $29.78. AnaptysBio has a 12-month low of $13.36 and a 12-month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The company had revenue of $10.97 million during the quarter, compared to analyst estimates of $25.85 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. On average, equities analysts forecast that AnaptysBio will post -6.84 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the company’s stock in a transaction dated Wednesday, August 14th. The shares were acquired at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the completion of the acquisition, the insider now owns 7,794,996 shares in the company, valued at approximately $284,517,354. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was purchased at an average cost of $36.50 per share, for a total transaction of $9,999,978.00. Following the transaction, the insider now directly owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the transaction, the insider now directly owns 15,398 shares of the company’s stock, valued at $595,440.66. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,440 shares of company stock valued at $892,936 in the last ninety days. 33.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AnaptysBio

A number of hedge funds have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC purchased a new position in AnaptysBio in the 1st quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of AnaptysBio in the 1st quarter valued at approximately $265,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of AnaptysBio during the first quarter worth $1,221,000. Acadian Asset Management LLC acquired a new stake in AnaptysBio during the first quarter worth about $420,000. Finally, Platinum Investment Management Ltd. acquired a new stake in shares of AnaptysBio during the 1st quarter worth approximately $1,490,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.